<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9346">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758589</url>
  </required_header>
  <id_info>
    <org_study_id>D9830C00004</org_study_id>
    <nct_id>NCT00758589</nct_id>
  </id_info>
  <brief_title>One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids</brief_title>
  <acronym>OLIVE</acronym>
  <official_title>A Double-blind, Randomised, Parallel Group, Multicentre Phase IIb, Placebo-Controlled, 1 Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Costa Rica: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate efficacy of AZD1981 in uncontrolled
      asthmatic patients on maintenance inhaled glucocorticosteroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Morning Peak Expiratory Flow (mPEF)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean mPEF during the treatment period (mean of the last 2 weeks of the treatment period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Expiratory Flow (ePEF)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean ePEF during the treatment period (mean of the last 2 weeks of the treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Forced Expiratory Volume in 1 Second (mFEV1)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean mFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Forced Expiratory Volume in 1 Second (eFEV1)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean eFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Use of Reliever</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean total reliever use during the treatment period (mean of the last 2 weeks of the treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time Asthma Symptom Score</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean night-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day-time Asthma Symptom Score</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean day-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Awakenings</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percentage of awakenings due to asthma symptoms during the treatment period (mean of the last 2 weeks of the treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Day</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percentage of asthma control days during the treatment period (mean of the last 2 weeks of the treatment period). An asthma control day is defined as a symptom-free day with no use of reliever medication during day and night. A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Free Day</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percentage of symptom free days during the treatment period (mean of the last 2 weeks of the treatment period). A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliever Free Day</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percentage of reliever free days during the treatment period (mean of the last 2 weeks of the treatment period). A reliever free day is defined as a day and a night with no use of as-needed medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) at the Clinic</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean FEV1 during the treatment period (mean value at Week 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at the Clinic</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean FVC during the treatment period (mean value at Week 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire 5 Items (ACQ5)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean ACQ5 score during the treatment period (mean value at Week 4). Scores range from 0 (good) to 6 (poor control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients reporting at least one event</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>AZD1981 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 50 mg Twice Daily (Bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 400 mg Twice Daily (Bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 1000 mg Twice Daily (Bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>Oral tablet, 50 mg twice daily</description>
    <arm_group_label>AZD1981 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>Oral tablet, 400 mg twice daily</description>
    <arm_group_label>AZD1981 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>Oral tablet, 1000 mg twice daily</description>
    <arm_group_label>AZD1981 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Six months history of asthma

          -  Daily use of inhaled glucocorticosteroids

          -  FEV1 40-85% of predicted normal

          -  Reversibility; increase in FEV1 more than 12% and 200 mL post-bronchodilator

        Exclusion Criteria:

          -  Other clinically relevant disease or disorders

          -  History of smoking of more than 10 pack years

          -  Respiratory infection within 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lodz, Lodz, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Brasil</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barrio Los Yoses</city>
        <state>San Jose</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco de Dos Rios</city>
        <state>San Jose</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdalsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznal</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turek</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Costa Rica</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 24, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2008</firstreceived_date>
  <firstreceived_results_date>July 1, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>510 patients enrolled, 368 were allocated to treatment and 350 completed the study. First patient entered the study on 16 September 2008 and the last patient finished the study on 13 July 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1981 50 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 50 mg, twice daily</description>
        </group>
        <group group_id="P2">
          <title>AZD1981 400 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 400 mg, twice daily</description>
        </group>
        <group group_id="P3">
          <title>AZD1981 1000 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 1000 mg, twice daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>placebo oral tablet, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Palm stopped to work</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD1981 50 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 50 mg, twice daily</description>
        </group>
        <group group_id="B2">
          <title>AZD1981 400 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 400 mg, twice daily</description>
        </group>
        <group group_id="B3">
          <title>AZD1981 1000 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 1000 mg, twice daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>placebo oral tablet, twice daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
                <measurement group_id="B2" value="90"/>
                <measurement group_id="B3" value="92"/>
                <measurement group_id="B4" value="91"/>
                <measurement group_id="B5" value="368"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="43.3" lower_limit="18" upper_limit="76"/>
                <measurement group_id="B2" value="43" lower_limit="18" upper_limit="79"/>
                <measurement group_id="B3" value="43.5" lower_limit="18" upper_limit="77"/>
                <measurement group_id="B4" value="45.7" lower_limit="18" upper_limit="77"/>
                <measurement group_id="B5" value="44.35" lower_limit="18" upper_limit="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="34"/>
                <measurement group_id="B4" value="33"/>
                <measurement group_id="B5" value="113"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="71"/>
                <measurement group_id="B3" value="58"/>
                <measurement group_id="B4" value="58"/>
                <measurement group_id="B5" value="255"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morning Peak Expiratory Flow (mPEF)</title>
        <description>Mean mPEF during the treatment period (mean of the last 2 weeks of the treatment period)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="89"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Morning Peak Expiratory Flow (mPEF)</title>
            <description>Mean mPEF during the treatment period (mean of the last 2 weeks of the treatment period)</description>
            <units>L/min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="346.42" spread="132.70" lower_limit="-245" upper_limit="334"/>
                  <measurement group_id="O2" value="362.54" spread="134.69" lower_limit="-131" upper_limit="213"/>
                  <measurement group_id="O3" value="352.87" spread="124.22" lower_limit="-158" upper_limit="219"/>
                  <measurement group_id="O4" value="329.75" spread="140.14" lower_limit="-283" upper_limit="158"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Expiratory Flow (ePEF)</title>
        <description>Mean ePEF during the treatment period (mean of the last 2 weeks of the treatment period)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="89"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evening Peak Expiratory Flow (ePEF)</title>
            <description>Mean ePEF during the treatment period (mean of the last 2 weeks of the treatment period)</description>
            <units>L/min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="359.83" spread="129.23" lower_limit="-192" upper_limit="315"/>
                  <measurement group_id="O2" value="378.98" spread="134.54" lower_limit="-179" upper_limit="262"/>
                  <measurement group_id="O3" value="368.70" spread="124.08" lower_limit="-149" upper_limit="225"/>
                  <measurement group_id="O4" value="348.87" spread="142.92" lower_limit="-202" upper_limit="197"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Forced Expiratory Volume in 1 Second (mFEV1)</title>
        <description>Mean mFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="71"/>
                  <measurement group_id="O4" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Morning Forced Expiratory Volume in 1 Second (mFEV1)</title>
            <description>Mean mFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)</description>
            <units>L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.45" spread="0.99" lower_limit="-1.24" upper_limit="1.80"/>
                  <measurement group_id="O2" value="2.65" spread="1.03" lower_limit="-1.41" upper_limit="1.04"/>
                  <measurement group_id="O3" value="2.53" spread="0.97" lower_limit="-0.503" upper_limit="0.843"/>
                  <measurement group_id="O4" value="2.31" spread="1.05" lower_limit="-2.21" upper_limit="1.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Forced Expiratory Volume in 1 Second (eFEV1)</title>
        <description>Mean eFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="66"/>
                  <measurement group_id="O3" value="73"/>
                  <measurement group_id="O4" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evening Forced Expiratory Volume in 1 Second (eFEV1)</title>
            <description>Mean eFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)</description>
            <units>L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.47" spread="0.95" lower_limit="-0.834" upper_limit="1.17"/>
                  <measurement group_id="O2" value="2.72" spread="1.02" lower_limit="-1.56" upper_limit="1.20"/>
                  <measurement group_id="O3" value="2.63" spread="0.98" lower_limit="-0.765" upper_limit="2.03"/>
                  <measurement group_id="O4" value="2.43" spread="1.06" lower_limit="-1.46" upper_limit="1.66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Use of Reliever</title>
        <description>Mean total reliever use during the treatment period (mean of the last 2 weeks of the treatment period)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Use of Reliever</title>
            <description>Mean total reliever use during the treatment period (mean of the last 2 weeks of the treatment period)</description>
            <units>Number of inhalations per day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.870" spread="2.475" lower_limit="-4.80" upper_limit="5.34"/>
                  <measurement group_id="O2" value="2.640" spread="2.303" lower_limit="-6.36" upper_limit="6.59"/>
                  <measurement group_id="O3" value="2.569" spread="2.210" lower_limit="-8.30" upper_limit="3.23"/>
                  <measurement group_id="O4" value="2.855" spread="2.430" lower_limit="-6.79" upper_limit="2.84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night-time Asthma Symptom Score</title>
        <description>Mean night-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Night-time Asthma Symptom Score</title>
            <description>Mean night-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.998" spread="0.633" lower_limit="-2.80" upper_limit="0.733"/>
                  <measurement group_id="O2" value="0.881" spread="0.543" lower_limit="-1.36" upper_limit="0.786"/>
                  <measurement group_id="O3" value="0.912" spread="0.594" lower_limit="-1.83" upper_limit="0.655"/>
                  <measurement group_id="O4" value="1.008" spread="0.614" lower_limit="-2.12" upper_limit="0.714"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day-time Asthma Symptom Score</title>
        <description>Mean day-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Day-time Asthma Symptom Score</title>
            <description>Mean day-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.037" spread="0.609" lower_limit="-2.80" upper_limit="0.850"/>
                  <measurement group_id="O2" value="0.933" spread="0.556" lower_limit="-1.00" upper_limit="1.04"/>
                  <measurement group_id="O3" value="0.995" spread="0.552" lower_limit="-2.20" upper_limit="1.25"/>
                  <measurement group_id="O4" value="1.105" spread="0.645" lower_limit="-2.00" upper_limit="1.62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Awakenings</title>
        <description>Mean percentage of awakenings due to asthma symptoms during the treatment period (mean of the last 2 weeks of the treatment period)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Awakenings</title>
            <description>Mean percentage of awakenings due to asthma symptoms during the treatment period (mean of the last 2 weeks of the treatment period)</description>
            <units>Percentage of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38.59" spread="40.25" lower_limit="-100" upper_limit="44.4"/>
                  <measurement group_id="O2" value="33.18" spread="38.93" lower_limit="-84.6" upper_limit="100"/>
                  <measurement group_id="O3" value="33.34" spread="37.68" lower_limit="-92.3" upper_limit="60"/>
                  <measurement group_id="O4" value="37.32" spread="39.51" lower_limit="-100" upper_limit="58.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Day</title>
        <description>Mean percentage of asthma control days during the treatment period (mean of the last 2 weeks of the treatment period). An asthma control day is defined as a symptom-free day with no use of reliever medication during day and night. A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Asthma Control Day</title>
            <description>Mean percentage of asthma control days during the treatment period (mean of the last 2 weeks of the treatment period). An asthma control day is defined as a symptom-free day with no use of reliever medication during day and night. A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.</description>
            <units>Percentage of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.78" spread="25.79" lower_limit="-12.5" upper_limit="100"/>
                  <measurement group_id="O2" value="7.48" spread="20.71" lower_limit="-20" upper_limit="100"/>
                  <measurement group_id="O3" value="13.23" spread="26.24" lower_limit="-38.3" upper_limit="100"/>
                  <measurement group_id="O4" value="10.08" spread="22.36" lower_limit="-1.67" upper_limit="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Free Day</title>
        <description>Mean percentage of symptom free days during the treatment period (mean of the last 2 weeks of the treatment period). A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Symptom Free Day</title>
            <description>Mean percentage of symptom free days during the treatment period (mean of the last 2 weeks of the treatment period). A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.</description>
            <units>Percentage of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.33" spread="32.16" lower_limit="-49.2" upper_limit="100"/>
                  <measurement group_id="O2" value="13.95" spread="28.35" lower_limit="-52.3" upper_limit="100"/>
                  <measurement group_id="O3" value="15.56" spread="28.51" lower_limit="-72.3" upper_limit="100"/>
                  <measurement group_id="O4" value="14.31" spread="26.28" lower_limit="-23.8" upper_limit="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reliever Free Day</title>
        <description>Mean percentage of reliever free days during the treatment period (mean of the last 2 weeks of the treatment period). A reliever free day is defined as a day and a night with no use of as-needed medication.</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Reliever Free Day</title>
            <description>Mean percentage of reliever free days during the treatment period (mean of the last 2 weeks of the treatment period). A reliever free day is defined as a day and a night with no use of as-needed medication.</description>
            <units>Percentage of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22.59" spread="34.57" lower_limit="-16.9" upper_limit="100"/>
                  <measurement group_id="O2" value="20.60" spread="32.01" lower_limit="-30.0" upper_limit="100"/>
                  <measurement group_id="O3" value="24.13" spread="32.12" lower_limit="-50.0" upper_limit="100"/>
                  <measurement group_id="O4" value="20.94" spread="32.97" lower_limit="-23.6" upper_limit="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) at the Clinic</title>
        <description>Mean FEV1 during the treatment period (mean value at Week 4)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Forced Expiratory Volume in 1 Second (FEV1) at the Clinic</title>
            <description>Mean FEV1 during the treatment period (mean value at Week 4)</description>
            <units>L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.653" spread="1.051" lower_limit="-0.760" upper_limit="2.02"/>
                  <measurement group_id="O2" value="2.739" spread="1.028" lower_limit="-0.730" upper_limit="2.16"/>
                  <measurement group_id="O3" value="2.628" spread="1.057" lower_limit="-2.46" upper_limit="2.04"/>
                  <measurement group_id="O4" value="2.400" spread="0.945" lower_limit="-0.740" upper_limit="1.26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at the Clinic</title>
        <description>Mean FVC during the treatment period (mean value at Week 4)</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Forced Vital Capacity (FVC) at the Clinic</title>
            <description>Mean FVC during the treatment period (mean value at Week 4)</description>
            <units>L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.704" spread="1.268" lower_limit="-1.48" upper_limit="2.21"/>
                  <measurement group_id="O2" value="3.892" spread="1.295" lower_limit="-0.980" upper_limit="2.30"/>
                  <measurement group_id="O3" value="3.546" spread="1.257" lower_limit="-1.03" upper_limit="2.68"/>
                  <measurement group_id="O4" value="3.563" spread="1.215" lower_limit="-0.990" upper_limit="2.02"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire 5 Items (ACQ5)</title>
        <description>Mean ACQ5 score during the treatment period (mean value at Week 4). Scores range from 0 (good) to 6 (poor control).</description>
        <time_frame>Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="89"/>
                  <measurement group_id="O3" value="86"/>
                  <measurement group_id="O4" value="85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Asthma Control Questionnaire 5 Items (ACQ5)</title>
            <description>Mean ACQ5 score during the treatment period (mean value at Week 4). Scores range from 0 (good) to 6 (poor control).</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.69" spread="-2.40" lower_limit="0" upper_limit="4.00"/>
                  <measurement group_id="O2" value="1.58" spread="-2.40" lower_limit="0" upper_limit="3.80"/>
                  <measurement group_id="O3" value="1.64" spread="-3.20" lower_limit="0" upper_limit="4.60"/>
                  <measurement group_id="O4" value="1.91" spread="-2.60" lower_limit="0" upper_limit="4.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event (AE)</title>
        <description>Number of patients reporting at least one event</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>AZD1981 50 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 50 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD1981 400 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 400 mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD1981 1000 mg Twice Daily (Bid)</title>
            <description>AZD1981 oral tablet 1000 mg, twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Event (AE)</title>
            <description>Number of patients reporting at least one event</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1981 50 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 50 mg, twice daily</description>
        </group>
        <group group_id="E2">
          <title>AZD1981 400 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 400 mg, twice daily</description>
        </group>
        <group group_id="E3">
          <title>AZD1981 1000 mg Twice Daily (Bid)</title>
          <description>AZD1981 oral tablet 1000 mg, twice daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo oral tablet, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.1">Gastritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Holt</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
